Terns Pharmaceuticals Raises $150.15 Million in an Upsized Public Offering
Terns Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering, bringing in $150.15 million in gross proceeds. The company, which focuses on developing treatments for serious conditions in oncology and obesity, framed the raise as a step toward moving its clinical programs forward and strengthening day-to-day operations. In short: more fuel for a pipeline that’s already in motion.
What’s in the Offering
The offering consists of 11,919,048 shares of common stock, each priced at $10.50. Alongside the common stock, Terns is also offering pre-funded warrants to purchase 2,380,952 additional shares, priced at $10.4999 per warrant. These figures are presented before any underwriter discounts and commissions. The structure, blending shares and pre-funded warrants, gives the company flexibility while aiming to support its broader financing plans.
Timing and Lead Banks
The transaction is expected to close shortly, subject to customary closing conditions. Jefferies and TD Cowen are serving as the lead book-running managers. They’re joined by BMO Capital Markets and UBS Investment Bank, which are also helping manage and place the offering. Together, the underwriting group is steering the process from pricing to close.
How Terns Plans to Use the Funds
Terns intends to direct the proceeds to core priorities across its business. That includes funding research, running clinical trials, advancing development, and supporting manufacturing for its key product candidates. Among those programs are TERN-701, TERN-601, and candidates within the TERN-800 series. Each sits within the company’s broader push to address difficult health problems where new small-molecule therapies could make a difference for patients.
Regulatory Filings and Offering Documents
The company filed a shelf registration statement for the securities on February 1, which has been declared effective by the Securities and Exchange Commission (SEC). In connection with the offering, Terns has also filed a prospectus supplement and an accompanying prospectus with the SEC. These documents are designed to provide investors with the details they need to understand the transaction and the associated risks before making any decision.
Where to Find More Information
Investors seeking additional information about the offering can obtain the prospectus and related materials from Jefferies or TD Securities. The company’s stated aim is to provide clear and complete information so interested investors can evaluate the opportunity with confidence.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on serious diseases, including cancers and metabolic conditions such as obesity. The company’s pipeline centers on small-molecule product candidates in clinical development, reflecting a strategy built around targeted, thoughtfully designed therapies. The aim is straightforward: develop treatments that can be rigorously tested, scaled, and, if successful, integrated into standards of care.
Pipeline and R&D Priorities
Terns’ programs include an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-? agonist. The company is also advancing work on GIPR modulators, with ongoing efforts to identify and refine candidates that could improve clinical outcomes. While each program targets a distinct mechanism, the common thread is the company’s emphasis on small molecules and the potential benefits that approach can offer in development and manufacturing.
Frequently Asked Questions
What is the total amount raised in Terns' latest offering?
Terns priced its upsized underwritten public offering at approximately $150.15 million in gross proceeds. That figure reflects the combined value of the common stock and the pre-funded warrants before underwriter discounts and commissions.
Who are the main underwriters for Terns' public offering?
Jefferies and TD Cowen are the lead book-running managers. BMO Capital Markets and UBS Investment Bank are also participating in the offering. This group is responsible for managing the deal from pricing through closing.
What are the intended uses of the proceeds from the offering?
The company plans to use the proceeds to fund research, clinical trials, development, and manufacturing across its pipeline. That includes work on TERN-701, TERN-601, and candidates in the TERN-800 series, as well as general corporate purposes tied to progressing these programs.
When is the offering expected to close?
The offering is expected to close shortly, subject to standard closing conditions. The timeline follows customary market practice for underwritten offerings.
What type of company is Terns Pharmaceuticals?
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing small-molecule product candidates for serious diseases, with a particular focus on oncology and metabolic conditions.
